ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

USDA Expands Role In 5 A Day Partnership

April 26, 2002

Cancer Center Planning Grants Recompetition Approved By Advisors

June 10, 1994

GM Corp, to Reimburse Marrow Transplants for Breast Cancer

March 15, 1996

Conversation With The Cancer Letter: PanCAN CEO Denies Bill Would Undermine NCI’s Role in Directing and Funding Research

August 3, 2012

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

October 14, 2005

ORI Must Release Documents In Fisher Case, Judge Rules

September 8, 1995